Engineering for Impact: Targeted Innovations for Personalized Management of Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) remains the most common subtype of non-Hodgkin lymphoma (NHL). While frontline regimens such as R-CHOP and pola-R-CHP achieve cure in many patients, outcomes remain suboptimal for severalpresentations, including those with double- or triple-hit and activated B-cell–type disease. Furthermore, many elderly or frail patients are ineligible for or cannot tolerate intensive frontline approaches. Despite incremental gains in frontline therapy, relapsed and refractory disease remains frequent, reflecting the limits of cytotoxic therapy in a molecularly heterogeneous cancer. To address these challenges, emerging targeted and cellular therapies – including  bispecific antibodies,  CAR T-cell therapies, antibody drug conjugates, and investigational agents such as Bruton’s tyrosine kinase inhibitors (BTKis) – offer new opportunities to improve outcomes across treatment lines. However, this rapid pace of innovation presents ongoing challenges for oncology clinicians in integrating molecular data, sequencing therapeutic options, and managing unique toxicity profiles.  

This highly interactive, enduring activity uses a journal club-inspired format to share recent advances with practicing clinicians and to explore how these innovations are shaping care today and may do so in the future.

At the conclusion of this activity, learners will be able to better:

• Interpret and apply molecular profiling results—including cell of origin and key genetic alterations—to guide risk stratification and treatment selection in patients with newly diagnosed and R/R DLBCL
• Evaluate available research data with and patient selection for BTKis in the frontline management of DLBCL to prepare for their potential availability in routine practice
• Assess recently approved and emerging strategies (e.g., BsAbs, BTKis, earlier use of approved agents) and their implications for personalized management of patients with DLBCL across the disease continuum

Supported through an independent educational grant from AstraZeneca Pharmaceuticals.

Hematologists, oncologists, hematology-oncology fellows, advanced practice practitioners, and pharmacists

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. LaCasce reports the following financial relationships:

Advisory Board: Caribou Biosciences, Inc.; Genmab; Kite Pharma; and Pierre Fabre Laboratories

Consultant: Takeda Pharmaceutical Company Limited

Dr. Matasar reports the following financial relationships:

Advisory Board: AbbVie Inc.; Allogene Therapeutics; Arvinas; Genentech USA, Inc.; Genmab; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Roche

Consultant: AbbVie Inc.; Allogene Therapeutics; Arvinas; Genentech USA, Inc.; Genmab; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.; and Roche

Grants: AbbVie Inc.; ADC Therapeutics; AstraZeneca; Epizyme, Inc.; HUTCHMED; Johnson & Johnson; Kite Pharma; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; and Roche

Research Support: Bayer; GM Biosciences, Inc.; ImmunoVaccine Technologies Inc.; Janssen Pharmaceuticals, Inc.; Genentech USA, Inc.; Pharmacyclics LLC; Roche; and Seattle Genetics, Inc.

Stock Shareholder (Ownership interest): Merck & Co., Inc.

Other financial or material support: Arnold & Porter (Expert Testimony)

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

WCV-124-022026-13